We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
-21.06%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$393M
AUM Growth
-$89.6M
(-19%)
Cap. Flow
+$13.6M
Cap. Flow
% of AUM
3.47%
Top 10 Holdings %
Top 10 Hldgs %
50.34%
Holding
56
New
13
Increased
11
Reduced
17
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADVM
Adverum Biotechnologies
ADVM
|
+$16.3M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$14.2M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
+$13.4M |
| 4 |
Invesco CurrencyShares British Pound Sterling Trust
FXB
|
+$12.6M |
| 5 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$10.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$20M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$15.8M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$10.9M |
| 4 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$9.02M |
| 5 |
Ascendis Pharma A/S
ASND
|
+$8.37M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Zymeworks
ZYME
$1.78B
| – | – |
-275,000
| Closed | -$6.05M |
|
|
GBT
52
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – |
-300,000
| Closed | -$15.8M |
|
|
ODT
53
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| – | – |
-65,000
| Closed | -$2.38M |
|
|
RARX
54
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| – | – |
-300,000
| Closed | -$9.02M |
|
|
ARQL
55
DELISTED
Arqule Inc
ARQL
| – | – |
-200,000
| Closed | -$2.2M |
|
|
ONCE
56
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| – | – |
-50,000
| Closed | -$5.12M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q3 2019 Portfolio in Review
As of Q3 2019, Ghost Tree Capital held 56 positions worth $393M, down 19% from $482M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Ghost Tree Capital deployed $13.6M of net new capital in Q3 2019, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Adverum Biotechnologies: 145,000 shares worth $7.9M.
By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 73% a quarter earlier.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $8.37M trimmed.
- Ghost Tree Capital's largest Q3 2019 buy was Adverum Biotechnologies: 145,000 shares worth $7.9M.
- Ghost Tree Capital added most to Sage Therapeutics in Q3 2019, an estimated $13.4M increase.
- Ghost Tree Capital's biggest Q3 2019 reduction was Ascendis Pharma A/S, cutting an estimated $8.37M.
- Ghost Tree Capital fully exited Acadia Pharmaceuticals in Q3 2019, selling an estimated $20M.
- Ghost Tree Capital's ten largest holdings make up 50% of its $393M portfolio in Q3 2019.
- Ghost Tree Capital opened 13 new positions and closed 12 in Q3 2019.
- Ghost Tree Capital's portfolio value fell 19% quarter-over-quarter to $393M.
Based on Ghost Tree Capital's 13F filing for Q3 2019, filed 14 Nov 2019.